Skip to content
No picture yet

Braftovi 75 mg – DIN 02513099

Braftovi is Encorafenib 75 mg (capsule), sold in Canada. It is used for melanoma. It is supplied by Pfizer Canada ULC. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Encorafenib 75 mg

Brand
Braftovi
Strength
75 mg
Used for
Melanoma
Form
Capsule
Manufacturer
Pfizer Canada ULC
Sold in
Canada
DIN
02513099

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Encorafenib pills and guides

What is Encorafenib used for?

Encorafenib is used for melanoma.

Official uses from the US prescribing label

BRAF V600E or V600K Mutation–Positive Unresectable or Metastatic Melanoma

BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test.

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC)

  • BRAFTOVI is indicated, in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-authorized test.
  • BRAFTOVI is indicated, in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-authorized test, after prior therapy.

BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

BRAFTOVI is indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test.

Limitations of Use

BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.

From the FDA-approved label on DailyMed (published Mar 02, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02513099.
  • It names Braftovi, Encorafenib 75 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Braftovi by Pfizer Canada ULC.

In Canada: prescription only.

Ingredients

Active: Encorafenib

Other Encorafenib pills